The mutagenic and antimitotic activities of the standard antituberculosis drug isoniazid and the immunomodulatory drug tubosan were compared using the Allium test, which took into account the frequency of chromosome aberrations, chromosome lagging, and micronuclei and allowed the mitotic and phase indices to be determined. It was established that isoniazid at concentrations 10, 60, and 120 mg/L inhibited fully the mitotic activity in tissues (for which the mitotic index was zero), implying that isoniazid exhibited very strong mitotoxic activity. The micronucleus test showed that the mutagenic activity of isoniazid increased with increasing concentration. The micronuclei induced by isoniazid were formed as a result of nuclear budding into the interphase. Isoniazid at a concentration of 300 mg/L led to the death of the test object. Tubosan at concentrations 60, 120, 800, and 1200 mg/L showed neither mutagenic nor antimitotic effects. The phase indices were also the same as those in the control. Thus, tubosan did not exhibit genotoxicity and could be classified as a genetically safe drug in the studied concentration range.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
B. S. Kibrik and O. G. Chelnokova, Immunochemotherapy of Tuberculosis. Bifunctional Drug Tubosan [in Russian], Moscow (2011), p. 154.;
B. S. Kibrik, O. G. Chelnokova, and R. V. Maistat, Antituberculosis and Immunomodulatory Activity of Tubosan in Experimental and Clinical Practice [in Russian], in: Materials of the TsNIIT RAMS Session, Moscow (2011), pp. 93–95.;
D. S. Pesnya, A. V. Romanovskii, I. M. Prokhorova, T. K. Artemova, et al., Biomed. Radioelektron., No. 4, 34–45 (2011).;
I. M. Prokhorova, A. N. Fomicheva, M. I. Kovaleva, and O. V. Babanazarova, Biol. Vnutr. Vod, No. 2, 17–23 (2008).;
V. A. Tarasov, Mutagens and Carcinogens in the Environment. New Approaches to Risk Evaluation for Health [in Russian], St. Petersburg (1998), pp. 15–30.;
V. V. N. Gopal Rao, E. V. Venkatarama Gupta, and I. M. Thomas, Mutat. Res., 259, 13–19 (1991).;
H. Takasawa, H. Suzuki, I. Ogawa, and Y. Shimada, Mutat. Res., 698, 30–37 (2010).;
N. M. Goloshchapov, E. N. Goloshchapova, et al., RU Pat. No. 2,141,322, Nov. 20, 1999.;
S. Cotelle, J. F. Masfaraud, and J. F. Ferard, Mutat. Res., 426, No. 2, 167–171 (1990).;
A. Majewska, E. Sliwinska, M. Wierzbicka, and M. Kuras, Caryologia, 61(1), 26–44 (2008).;
A. Barberrio, J. C. Voltolini, and M. L. S. Mello, Ecotoxicology, 20(4), 927–935 (2011).;
M. Ghosh, A. Chakraborty, M. Bandyopadhyay, and A. Mukherjee, J. Hazard. Mater., 197, 327–336 (2011).;
A. H. Siddiqui, S. Tabrez, and M. Ahmad, Environ. Monit. Assess., 179, 241–253 (2011).;
H. K. Lindberg, X. Wang, H. Jarventaus, et al., Mutat. Res., 617, 33–45 (2007).
Author information
Authors and Affiliations
Additional information
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 47, No. 5, pp. 29 – 31, May, 2013.
Rights and permissions
About this article
Cite this article
Kibrik, B.S., Prokhorova, I.M. & Pesnya, D.S. Mutagenic and antimitotic activity of the immunomodulatory drug tubosan. Pharm Chem J 47, 261–263 (2013). https://doi.org/10.1007/s11094-013-0941-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-013-0941-2